Blood Test Shows Promise for Pancreatic Insufficiency

Patients who struggle to complete stool-based testing may one day have a blood-draw alternative, pending larger validation studies.

Updated on Nov. 6, 2026 in Diabetes

Isometric editorial illustration of a single glass blood-collection vial on a steel tray, in muted teal, cream, and oxblood tones.
A preliminary pilot study presented at the American College of Gastroenterology's annual meeting found a blood test may match stool testing for exocrine pancreatic insufficiency. AI Illustration. Upload story photo >

A pilot study presented at the American College of Gastroenterology's Annual Scientific Meeting in Nashville found a blood-based marker, apolipoprotein A2 isoform, performed comparably to fecal elastase in identifying exocrine pancreatic insufficiency. The findings are preliminary and could matter for patients who struggle to complete stool-based testing.

Why it matters

Fecal elastase is the recommended test for exocrine pancreatic insufficiency, but its completion rates of roughly 25% to 40% leave many patients without a diagnosis. A blood test that avoids stool collection could widen access, though the study was too small to establish it as a replacement.

This pilot study enrolled 72 patients who consented, with 71 providing blood samples, and classified 44 as having normal exocrine function, 15 with mild or moderate insufficiency, and 12 with severe insufficiency. The blood marker performed comparably to fecal elastase, though larger studies are still needed to confirm these results.

The players

American College of Gastroenterology

A professional medical society representing gastroenterologists, whose annual meeting is a major venue for presenting clinical digestive disease research.

The Ohio State University Wexner Medical Center

A major academic medical center in Columbus, Ohio, whose researchers led the pilot study on the blood-based biomarker.

The details

Exocrine pancreatic insufficiency means the pancreas does not release enough digestive enzymes, which can impair the breakdown of food. In this study, researchers measured apolipoprotein A2 isoforms in blood drawn from participants who had already completed fecal elastase testing, and investigators were blinded to the blood results during adjudication. The marker showed a strong association with the presence and severity of the condition, although it did not surpass the established stool and enzyme tests in overall accuracy.

Timeline

  1. Nov. 5, 2026: Study presented at the American College of Gastroenterology Annual Scientific Meeting in Nashville, Tennessee.

Health Landscape

Fecal elastase remains the standard diagnostic test for exocrine pancreatic insufficiency, but its limited completion rates and false low results in patients with watery diarrhea have long constrained clinical diagnosis. This pilot blood marker is an early attempt to offer a diagnostic option that does not depend on stool collection.

If you have persistent greasy stools, unexplained weight loss, or bloating, these symptoms are worth raising with your doctor, who can determine which tests are appropriate. Blood-based options may eventually offer an alternative for people who find stool collection difficult, but this approach is not yet available in routine care.

The takeaway

A blood-based marker may one day give clinicians another way to diagnose exocrine pancreatic insufficiency when stool testing is difficult. Until larger studies confirm the findings, ask your doctor about the testing options currently available.

Further reading

For more on how digestive conditions connect to blood sugar and metabolic health, explore our Diabetes coverage.

Source note: This article includes information reported by Healio.